UK’s NICE grants ac­cess to Amar­in's cho­les­terol drug amid US staff cuts

The UK’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence, or NICE, on Fri­day agreed to cov­er Amarin’s con­tro­ver­sial cho­les­terol drug Vas­cepa, amidst tur­bu­lence for Amarin.

Amarin and NICE agreed to a price of £144.21 per 120 soft cap­sules (or $181 for 30-day sup­ply), ac­cord­ing to Amarin. Low-price gener­ic ver­sions of Vas­cepa, known as icos­apent eth­yl, cost about $100 in the US, ac­cord­ing to GoodRx.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER